⚕ GalenOps CRO console
← SITE005 (FRA)

SITE005-0396

completed
Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE005 (FRA) (Dr. Muller) · consented 2023-07-02
Adverse events
7
Serious AEs
1
Open data queries
0
Luna dropout signal
–

Adverse events

moderate assessed 2026-08-18

Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-08-11 (study day 25); relationship: not assessed

severe serious assessed 2026-08-18

Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-08-11 (study day 25); relationship: N; serious criteria: hospitalization

moderate assessed 2026-08-18

Grade 2 Aspartate aminotransferase increased — outcome: RECOVERED/RESOLVED; onset 2023-08-14 (study day 28); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2023-08-16 (study day 30); relationship: N

mild assessed 2026-08-18

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-08-27 (study day 41); relationship: N

mild assessed 2026-08-18

Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-08-29 (study day 43); relationship: N

mild assessed 2026-08-18

Grade 1 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-09-21 (study day 66); relationship: not assessed

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.